Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00304278 · ClinicalTrials.gov registry record · Phase 2
Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)
A Phase 2 study, sponsored by Southern Illinois University.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00304278: Completed Phase 2 study, sponsored by Southern Illinois University.
NCT00304278 is a Phase 2 study that has completed, run by Southern Illinois University. The registered enrollment target is 21 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00304278, a Phase 2 study, has completed, sponsored by Southern Illinois University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectiveness of treatment with Tarceva (Erlotinib) and RADPLAT (RADiation and intraarterial cisPLATin) for patients with Head and Neck cancer
Primary Outcome
Complete and Partial Response as defined by RECIST 1.0. Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD
Interventions
- DRUG Erlotinib (Tarceva)
- DRUG Intra-arterial Cisplatin (PLAT)
- RADIATION Radiation Therapy (RAD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2006-03 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
What the finished NCT00304278 record still lists
NCT00304278 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 3 interventions - of which Erlotinib (Tarceva) is the first listed.
NCT00304278 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00304278 about?
NCT00304278 is a clinical study titled "Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)". The purpose of this study is to determine the safety and effectiveness of treatment with Tarceva (Erlotinib) and RADPLAT (RADiation and intraarterial cisPLATin) for patients with Head and Neck cancer
What is the current status of trial NCT00304278?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2006-03. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00304278?
The interventions under investigation include: Erlotinib (Tarceva) (DRUG), Intra-arterial Cisplatin (PLAT) (DRUG), Radiation Therapy (RAD) (RADIATION).
Who is sponsoring clinical trial NCT00304278?
This trial is sponsored by Southern Illinois University, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00304278's enrollment target sits among peer trials
21 1794th of 2000 higher than 196 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia